Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 5/20 | 0.59 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 6/20 | 0.57 |
| ▸ | CA2 | P00918 | 6/20 | 0.57 |
| ▸ | CA12 | O43570 | 4/20 | 0.57 |
| ▸ | CA4 | P22748 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | CA6 | P23280 | 3/20 | 0.57 |
| ▸ | CA5A | P35218 | 3/20 | 0.57 |
| ▸ | CA7 | P43166 | 3/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | CA3 | P07451 | 2/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28469589 | 0.84 | CA1 (0.60) | CA9CA1CA2CA12CA4 | |
| SCHEMBL7629070 | 0.82 | SMN1; SMN2 (0.80) | CA9CA1CA2CA12CA4 | |
| SCHEMBL1014348 | 0.81 | HTR6 (0.55) | PSIP1SMN1; SMN2GAALMNAHTR6 | |
| SCHEMBL3702441 | 0.81 | UCHL1 (0.59) | CA9CA1CA2CA12CA4 | |
| SCHEMBL25619933 | 0.80 | PSIP1 (0.55) | CA9PSIP1CA1CA2CA12 | |
| SCHEMBL1751929 | 0.80 | SMN1; SMN2 (0.53) | CA9CA1CA2CA12CA4 | |
| SCHEMBL1751926 | 0.80 | SMN1; SMN2 (0.53) | CA9CA1CA2CA12CA4 | |
| SCHEMBL4615358 | 0.80 | ALDH1A1 (0.63) | CA9PSIP1CA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL4636143 | 0.80 | HTR6 (0.54) | PSIP1CA1CA2SMN1; SMN2GAA | |
| SCHEMBL1752461 | 0.79 | SMN1; SMN2 (0.57) | CA9CA1CA2CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937652-B1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMA INC (US) | 2014-07-30 | — | — | EP | claimed |
| WO-2025021943-A1 | QUINAZOLINONE, BENZOXAZINONE AND BENZOXAZEPINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NEURALIS (BE) | 2025-01-30 | — | — | WO | disclosed |
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2022-12-27 | — | — | US | disclosed |
| CN-109206360-B | Carbazole amide derivative or salt thereof, and preparation method and application thereof | 复旦大学 | 2022-05-17 | — | — | CN | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| WO-2021262910-A2 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3476829-B1 | BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME | UNIV FUDAN (CN) | 2021-12-15 | — | — | EP | disclosed |
| US-20210238174-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-08-05 | — | — | US | disclosed |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2021-04-01 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287365-A1 | Substituted arylpyrazoles | ZOETIS LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-7067541-B2 | 2-amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1633714-A1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | Pfizer Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| US-20050004182-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| WO-2004108675-A1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
| US-20040235833-A1 | Indole derivatives useful for the treatment of diseases | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| EP-1460064-A1 | Indole-2-carboxamide derivatives useful as beta-2 agonists | Pfizer Limited (GB) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003055866-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | CA9 3381/4885PSIP1 1503/4885CA1 4385/4885 |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | CA9 4833/4885PSIP1 3509/4885CA1 4237/4885 |
| US-20210238174-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | CA9 2238/4885PSIP1 2094/4885CA1 2174/4885 |
| US-20060287365-A1 | Substituted arylpyrazoles | CYP3A4, CYP3A43, CYP4B1 | CA9 2702/4885PSIP1 1740/4885CA1 3510/4885 |
| US-20210094940-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | CA9 2621/4885PSIP1 3311/4885CA1 2386/4885 |
| US-20050004182-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PAH, AADAT, IL4I1 | CA9 3415/4885PSIP1 3497/4885CA1 3439/4885 |
| US-11535614-B2 | Dihydropyrrolopyridine inhibitors of ROR-gamma | RORC, RORB, RORA | CA9 2238/4885PSIP1 2094/4885CA1 2174/4885 |
| US-20040235833-A1 | Indole derivatives useful for the treatment of diseases | IDO1, IDO2, INMT | CA9 2808/4885PSIP1 3415/4885CA1 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.